Can-Fite BioPharma is a clinical-stage biopharmaceutical company developing small molecule therapeutics targeting cancer, liver diseases, inflammation, and erectile dysfunction. Its lead drug candidate Piclidenoson (CF101) is in Phase III trials for psoriasis and rheumatoid arthritis. Namodenoson (CF102), another key product, is in Phase IIb trials for non-alcoholic steatohepatitis and Phase III for hepatocellular carcinoma.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.